Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prediction of Vedolizumab efficacy in induction and maintenance therapy for ulcerative colitis
ChiCTR2200063027Phase 4Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vedolizumab in autoimmune colitis, sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: Clinical remission at week 22, Clinical remission at week 54 and 4 more. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on ChiCTR2200063027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063027.